Ruixiang Zhang
Overview
Explore the profile of Ruixiang Zhang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
329
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang R, Nie Y, Chen X, Jiang T, Wang J, Peng Y, et al.
J Clin Invest
. 2025 Feb;
PMID: 39998886
Background: Current methods for detecting esophageal cancer (EC) are generally invasive or exhibit limited sensitivity and specificity, especially for the identification of early-stage tumors. Methods: We identified potential methylated DNA...
2.
Wang P, Wang S, Huang Q, Chen X, Yu Y, Zhang R, et al.
BMC Med
. 2025 Feb;
23(1):113.
PMID: 39988705
Background: Systemic nutrition and inflammation status is recognized for its influence on cancer survival, yet its role in perioperative outcomes remains poorly defined. This study aimed to refine the assessment...
3.
Yang Y, Xue L, Chen X, Kang M, Zhang R, Tian H, et al.
Thorac Cancer
. 2025 Jan;
16(1):e15504.
PMID: 39777993
Objectives: This study aimed to analyze lymph node metastasis (LNM) distribution in superficial esophageal squamous cell carcinoma (ESCC) and its impact factors on survival. Methods: We reviewed 241 pT1N+ ESCC...
4.
Wang D, Liu L, Chi W, Liu Z, Wu J, Liang Y, et al.
Adv Sci (Weinh)
. 2024 Dec;
12(4):e2409708.
PMID: 39630008
Tumor-derived cell-free DNA (cfDNA) has been exploited as an effective liquid biopsy biomarker for early cancer diagnosis. However, the fragmented and low-abundance nature in circulating blood pose challenges for highly...
5.
Wang X, Kang X, Zhang R, Xue L, Xu J, Zhao X, et al.
Clin Cancer Res
. 2024 Nov;
30(22):5061-5072.
PMID: 39544026
Purpose: This phase II trial investigated the safety and efficacy of chemoradiotherapy (CRT) followed by immunochemotherapy (iCT) and surgery in unresectable locally advanced esophageal squamous cell carcinoma (ESCC). Patients And...
6.
Wang X, Feng G, Yang X, Yu N, Zheng Z, Li J, et al.
Cancer Biol Ther
. 2024 Oct;
25(1):2417464.
PMID: 39462770
Purpose: This prospective study in a real-world setting investigated the feasibility and safety of S-1 plus nimotuzumab (S-1-Nimo) based concurrent chemoradiotherapy (CCRT) in locally advanced esophageal squamous cell carcinoma (LA-ESCC)...
7.
Huang W, Liu X, Li X, Zhang R, Chen G, Mao X, et al.
Front Endocrinol (Lausanne)
. 2024 Oct;
15:1438821.
PMID: 39387049
Objective: To explore the pharmacodynamic ingredients and pharmacologic mechanism of Haizao Yuhu Decoction (HYD) in treating hyperthyroidism via an analysis integrating network pharmacology, molecular docking, and non-targeted serum metabolomics. Methods:...
8.
Yu N, Chen X, Li J, Kang X, Wang Z, Zhang R, et al.
Strahlenther Onkol
. 2024 Aug;
200(12):1038-1046.
PMID: 39134689
Background: To evaluate the efficacy and safety of nab-paclitaxel plus cisplatin as the regimen of conversional chemoradiotherapy (cCRT) in locally advanced borderline resectable or unresectable esophageal squamous cell carcinoma (ESCC)....
9.
Zhang R, Wang Z, Kang X, Wang X, Zhang B, Ng H, et al.
J Natl Cancer Cent
. 2024 Jul;
3(3):167-174.
PMID: 39035198
Esophageal cancer (EC) is particularly common in China. With the continuing progress of multi-disciplinary therapy including early screening, minimally invasive techniques, radiotherapy and chemotherapy, the 5-year survival of EC has...
10.
Wang Z, Chen X, Li Y, Qin J, Fang Y, Yang Z, et al.
J Natl Cancer Cent
. 2024 Jul;
2(2):98-105.
PMID: 39034958
Objective: This is a prospective, single-arm, phase Ib study to evaluate the safety and efficacy of camrelizumab combined with chemotherapy and apatinib as neoadjuvant therapy for locally advanced thoracic esophageal...